NCT02948946View on ClinicalTrials.gov

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

CompletedOBSERVATIONAL
Enrollment

105

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

August 24, 2018

Study Completion Date

September 15, 2020

Conditions
Gastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm
Interventions
PROCEDURE

NETest

5 mL of blood will be drawn from participants for testing.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02948946 - Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter